US Regulator Approves Pfizer's RSV Vaccine for Adults 60 and Older
Headline from Voice of America
Pfizer's vaccine was 67% effective among those aged 60 and older with two or more symptoms of RSV, and 85.7% effective against severe illness defined by three or more symptoms
Voice of America's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
By Jamie Gumbrecht, CNN (CNN) — The US Food and Drug Administration on Wednesday approved Pfizer’s RSV vaccine for older adults, the second such shot approved for the common virus. Earlier in May, the agency approved the world’s first RSV vaccine for older adults, made by GSK.
THURSDAY, June 1, 2023 (HealthDay News) -- Older adults may have a second vaccine option for RSV following the U.S. Food and Drug Administration's approval of a Pfizer vaccine on
Pfizer's vaccine was 67% effective among those aged 60 and older with two or more symptoms of RSV, and 85.7% effective against severe illness defined by three or more symptoms
The U.S. Food and Drug Administration approved Pfizer's respiratory syncytial virus vaccine on Wednesday. The vaccine, called ABRYSVO, is the second RSV vaccine for people older than 60 to be approved by the FDA.
